Halozyme Therapeutics : SWOG To Resume Trial In Advanced Pancreatic Cancer Drug

(RTTNews) - Halozyme Therapeutics Inc. (HALO) said that SWOG will resume clinical trial of halozyme's PEGPH20 in combination with modified folfirinox for advanced pancreatic cancer.

The company announced that the U.S. Food and Drug Administration or FDA has removed the clinical hold on patient enrollment and dosing of PEGPH20 in SWOG's ongoing Phase 1b/2 clinical trial (S1313).

The trial is designed to evaluate Halozyme's investigational drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination with modified FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma.

The company noted that the study will resume under a revised protocol, and patient enrollment is anticipated to recommence upon review and approval of the amended protocol by the Independent Review Boards at the participating clinical trial sites.

The trial is being sponsored by SWOG, a cancer research cooperative group of about 5,000 researchers in more than 650 institutions nationwide. The trial will enroll approximately 170 patients.